Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36277
Title: | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial | Authors: | Vermersch, Patrick Oreja-Guevara, Celia Siva, Aksel VAN WIJMEERSCH, Bart Wiendl, Heinz Wuerfel, Jens Buffels, Regine Kadner, Karen Kuenzel, Thomas Comi, Giancarlo |
Issue Date: | 2022 | Publisher: | WILEY | Source: | EUROPEAN JOURNAL OF NEUROLOGY, 29(3), p. 790-801 | Abstract: | Background and purpose Using the treatment goal of "no evidence of disease activity" (NEDA) incorporating magnetic resonance imaging (MRI) re-baselining, we aimed to assess the efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a prior suboptimal response, defined by MRI or relapse criteria, to one or two disease-modifying therapies (DMTs). Methods CASTING was a prospective, international, multicenter, single-arm, open-label phase 3 trial (NCT02861014). Patients (Expanded Disability Status Scale [EDSS] score <= 4.0, with discontinued prior DMT of >= 6 months duration due to suboptimal disease control) received intravenous ocrelizumab 600 mg every 24 weeks for 96 weeks. The primary endpoint was NEDA (defined as absence of relapses, disability progression, and inflammatory MRI measures, with prespecified MRI re-baselining at Week 8) over 96 weeks. Results A total of 680 patients were enrolled, 167 (24.6%) based on MRI activity only. At Week 96, 74.8% (95% confidence interval [CI] 71.3-78.0, n/N = 492/658) of patients had NEDA. NEDA was highest among patients enrolled due to MRI activity alone (80.6% [95% CI 68.6-89.6], n/N = 50/62) versus those enrolled for relapse (75.1% [95% CI 69.0-80.6], n/N = 172/229) or for relapse with MRI (70.5% [95% CI 60.0-79.0], n/N = 74/105). NEDA across subgroups was highest in patients with a baseline EDSS score <2.5 (77.2% [95% CI 72.8-81.2], n/N = 315/408). NEDA was higher in patients receiving one prior DMT (77.6% [95% CI 73.2-81.6], n/N = 312/402) versus two prior DMTs (70.3% [95% CI 64.3-75.8], n/N = 180/256). Conclusions In patients switching therapy due to suboptimal disease control, treatment with ocrelizumab led to an overall high NEDA rate across a wide range of disease-related and demographic subgroups, regardless of prior treatment background, with no new safety signals detected. | Notes: | Vermersch, P (corresponding author), Univ Lille, CHU Lille, FHU Precise, INSERM,U1172,LilNCog, Lille, France. patrick.vermersch@univ-lille.fr |
Keywords: | disease activity;disease-modifying therapies;multiple sclerosis;ocrelizumab;relapsing-remitting multiple sclerosis | Document URI: | http://hdl.handle.net/1942/36277 | ISSN: | 1351-5101 | e-ISSN: | 1468-1331 | DOI: | 10.1111/ene.15171 | ISI #: | WOS:000722452500001 | Rights: | 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2022 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Euro J of Neurology - 2021 - Vermersch - Efficacy and safety of ocrelizumab in patients with relapsingāremitting multiple.pdf | Published version | 598.92 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
14
checked on Apr 14, 2024
Page view(s)
20
checked on Sep 7, 2022
Download(s)
38
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.